NO310617B1 - Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter - Google Patents

Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter Download PDF

Info

Publication number
NO310617B1
NO310617B1 NO19972591A NO972591A NO310617B1 NO 310617 B1 NO310617 B1 NO 310617B1 NO 19972591 A NO19972591 A NO 19972591A NO 972591 A NO972591 A NO 972591A NO 310617 B1 NO310617 B1 NO 310617B1
Authority
NO
Norway
Prior art keywords
compound
quinoline
tetrahydro
trifluoromethyl
dihydro
Prior art date
Application number
NO19972591A
Other languages
English (en)
Norwegian (no)
Other versions
NO972591L (no
NO972591D0 (no
Inventor
Todd Kevin Jones
Mark E Goldman
Charlotte L F Pooley
David T Winn
James E Edwards
Sarah J West
Christopher M Tegley
Lin Zhi
Lawrence G Hamann
Luc J Farmer
Robert J Davis
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/464,360 external-priority patent/US5693646A/en
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of NO972591D0 publication Critical patent/NO972591D0/no
Publication of NO972591L publication Critical patent/NO972591L/no
Publication of NO310617B1 publication Critical patent/NO310617B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO19972591A 1994-12-22 1997-06-06 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter NO310617B1 (no)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US36352994A 1994-12-22 1994-12-22
US08/464,360 US5693646A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,541 US5688810A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/465,556 US5696133A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/465,429 US5696127A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,546 US5693647A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/462,643 US5696130A (en) 1994-12-22 1995-06-05 Tricyclic steroid receptor modulator compounds and methods
US08/463,231 US5688808A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
PCT/US1995/016096 WO1996019458A2 (en) 1994-12-22 1995-12-13 Steroid receptor modulator compounds and methods

Publications (3)

Publication Number Publication Date
NO972591D0 NO972591D0 (no) 1997-06-06
NO972591L NO972591L (no) 1997-08-14
NO310617B1 true NO310617B1 (no) 2001-07-30

Family

ID=27575415

Family Applications (5)

Application Number Title Priority Date Filing Date
NO19972591A NO310617B1 (no) 1994-12-22 1997-06-06 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter
NO20003534A NO312162B1 (no) 1994-12-22 2000-07-07 Progesteronreseptor-modulatorforbindelser, farmasöytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
NO20003550A NO20003550D0 (no) 1994-12-22 2000-07-10 Farmasøytiske sammensetninger og anvendelse herav
NO20003551A NO312098B1 (no) 1994-12-22 2000-07-10 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse samt anvendelse avforbindelsene
NO20003552A NO313049B1 (no) 1994-12-22 2000-07-10 Progesteron-agonistforbindelser, farmasöytiske preparater inneholdende disse og anvendelsen av forbindelsen

Family Applications After (4)

Application Number Title Priority Date Filing Date
NO20003534A NO312162B1 (no) 1994-12-22 2000-07-07 Progesteronreseptor-modulatorforbindelser, farmasöytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
NO20003550A NO20003550D0 (no) 1994-12-22 2000-07-10 Farmasøytiske sammensetninger og anvendelse herav
NO20003551A NO312098B1 (no) 1994-12-22 2000-07-10 Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse samt anvendelse avforbindelsene
NO20003552A NO313049B1 (no) 1994-12-22 2000-07-10 Progesteron-agonistforbindelser, farmasöytiske preparater inneholdende disse og anvendelsen av forbindelsen

Country Status (17)

Country Link
EP (7) EP1043325B1 (de)
JP (2) JPH10510840A (de)
CN (2) CN1172917C (de)
AT (2) ATE252560T1 (de)
AU (1) AU717251B2 (de)
BR (1) BR9510486A (de)
CA (1) CA2208347A1 (de)
CZ (1) CZ176197A3 (de)
DE (2) DE69533180T2 (de)
DK (1) DK0800519T3 (de)
ES (1) ES2208699T3 (de)
HU (1) HUT78117A (de)
NO (5) NO310617B1 (de)
NZ (1) NZ300739A (de)
PT (1) PT800519E (de)
RU (1) RU2191774C2 (de)
WO (1) WO1996019458A2 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
DE69709752T2 (de) * 1996-06-27 2002-07-18 Ligand Pharm Inc Androgen rezeptor modulator verbindungen und verfahren
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
AU5729098A (en) * 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US6291442B1 (en) 1998-02-03 2001-09-18 The General Hospital Corporation Pharmacological modulators of voltage-gated potassium ion channels
US6380207B2 (en) * 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
AU766441B2 (en) * 1998-02-13 2003-10-16 Abbott Laboratories Glucocorticoid-selective anti-inflammatory agents
US6506766B1 (en) * 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6001846A (en) * 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
US6093825A (en) * 1998-05-27 2000-07-25 American Home Products Methods for preparation of 1,2-dihydroquinolines
US6093826A (en) * 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
CA2334545A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
CZ20013951A3 (cs) * 1999-05-04 2002-05-15 American Home Products Corporation Deriváty cyklokarbamátu jako modulátory receptoru pro progesteron
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
EP1175422A2 (de) * 1999-05-04 2002-01-30 Ligand Pharmaceuticals Incorporated Tetracyclische progesteronrezeptor-modulator-verbindungen und verfahren
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
BR0010214A (pt) * 1999-05-04 2002-02-13 American Home Prod Derivados de ciclotiocarbamato como moduladores de receptores de progesterona
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
JP2003508402A (ja) 1999-08-27 2003-03-04 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲン受容体モジュレーター化合物および方法
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (de) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituierte-6-trifluoromethyl-9-pyrido[3,2-g]chiolinverbindungen als androgen rezeptormodulatoren
KR100864547B1 (ko) * 1999-08-31 2008-10-20 바이엘 쉐링 파마 악티엔게젤샤프트 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질)
CO5200852A1 (es) 1999-09-14 2002-09-27 Lilly Co Eli Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides
KR100731566B1 (ko) * 1999-10-14 2007-06-22 가켄 세야쿠 가부시키가이샤 테트라히드로퀴놀린 유도체
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AU2002215609A1 (en) * 2000-06-28 2002-01-08 Bristol-Myers Squibb Company Fused cyclic compounds as modulators of nuclear hormone receptor function
CA2420289A1 (en) * 2000-08-23 2002-02-28 Akzo Nobel N.V. 10-aryl-11-hbenzo [b]fluorene derivatives and analogs for medicinal use
WO2002022585A1 (fr) * 2000-09-14 2002-03-21 Kaken Pharmaceutical Co., Ltd. Composes de tetrahydroquinoline
GEP20074144B (en) * 2000-09-19 2007-07-10 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
WO2003002548A1 (en) * 2001-06-29 2003-01-09 Abbott Laboratories A process for the preparation of chiral glucocorticoid receptor agents
US6608216B2 (en) 2001-06-29 2003-08-19 Abbott Laboratories Process for the preparation of chiral glucocorticoid receptor agents
CZ20042A3 (en) 2001-07-02 2004-04-14 Akzo Nobel N. V. Tetrahydroquinoline derivatives
JP2003073374A (ja) * 2001-08-31 2003-03-12 Kaken Pharmaceut Co Ltd 2環性芳香族アミン誘導体
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
ES2276038T3 (es) 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
TW200304371A (en) 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
JP2006508893A (ja) 2002-03-15 2006-03-16 イーライ・リリー・アンド・カンパニー ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−2−オン誘導体
AU2003230700A1 (en) 2002-03-26 2003-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6903215B2 (en) 2002-03-26 2005-06-07 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2484340C (en) * 2002-04-26 2011-05-03 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ATE403648T1 (de) 2002-08-21 2008-08-15 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
EP2298315A1 (de) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutische Behandlungsmethoden
EP1558618A1 (de) * 2002-10-11 2005-08-03 Ligand Pharmaceuticals, Inc. 5-(1Ü,1Ü-CYCLOALKYL/ALKENYL)METHYLIDEN-1,2-DIHYDRO-5H-CHROMENOç3,4-F!CHINOLINEALS DEN PROGESTERONREZEPTOR SELEKTIV MODULIERENDE VERBINDUNGEN
WO2004033460A1 (en) 2002-10-11 2004-04-22 Ligand Pharmaceuticals Incorporated 5-cycloalkenyl 5h-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
EP1567487A4 (de) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
CA2512257A1 (en) 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
CN1795177A (zh) * 2003-03-28 2006-06-28 辉瑞产品公司 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , -取代的1,2,3,4,-四氢-和1,2二氢-喹啉以及1, 2 , 3 , 4-四氢-喹喔啉衍生物
MXPA06001751A (es) 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
JP4468369B2 (ja) 2003-10-16 2010-05-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ある種のトリフルオロメチル置換アルコールの立体選択的合成
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
KR20070061536A (ko) 2004-09-07 2007-06-13 와이어쓰 6H-[1]벤조피라노[4,3-b]퀴놀린 및 에스트로겐제제로서의 이의 용도
US7635711B2 (en) 2004-12-27 2009-12-22 Boehringer-Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
KR101293935B1 (ko) 2005-06-17 2013-08-08 리간드 파마슈티칼스 인코포레이티드 안드로겐 수용체 조절 화합물 및 방법
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
JP4825636B2 (ja) * 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2−ジヒドロキノリン誘導体
WO2007032556A1 (ja) 2005-09-14 2007-03-22 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する新規1,2−ジヒドロキノリン誘導体
US20090203725A1 (en) * 2005-12-21 2009-08-13 Cornelis Arjan Van Oeveren Androgen Receptor Modulator Compounds and Methods
JP4898635B2 (ja) 2006-11-14 2012-03-21 参天製薬株式会社 置換フェニルアミノ低級アルキル基とエステル構造を導入したフェニル基を置換基として有する新規1,2−ジヒドロキノリン誘導体
JP2010512331A (ja) 2006-12-06 2010-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
WO2008111632A1 (ja) * 2007-03-13 2008-09-18 Santen Pharmaceutical Co., Ltd. 2,2,4-トリメチル-6-フェニル-1,2-ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2009103007A2 (en) * 2008-02-13 2009-08-20 Ligand Pharmaceuticals Incorporated Steroid hormone receptor modulator compounds and methods
CN102089283B (zh) * 2008-05-12 2015-11-25 步制药股份有限公司 含有具有取代氧基的2,2,4-三甲基-6-苯基-1,2-二氢喹啉衍生物的糖皮质激素受体激动剂
EP2130831A1 (de) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25-Hemmer
MX2010013095A (es) 2008-06-06 2010-12-21 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
CN103613538B (zh) * 2013-11-22 2015-05-20 山东斯递尔化工科技有限公司 一种2,2,4-三甲基-1,2-二氢化喹啉聚合体的催化合成工艺
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN107530435A (zh) 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
AU2016305092B2 (en) 2015-08-13 2022-01-27 Corcept Therapeutics, Inc. Method for differentially diagnosing ACTH-dependent Cushing's syndrome
EP3405101B1 (de) 2016-01-19 2020-12-23 Corcept Therapeutics, Inc. Differentialdiagnose von ektopischem cushing-syndrom
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用
EP3641780A4 (de) 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. Verfahren zur behandlung von neuroepitheltumoren unter verwendung selektiver glucocorticoidrezeptormodulatoren
CN107805248A (zh) * 2017-11-01 2018-03-16 长春海谱润斯科技有限公司 一种含有苯并咪唑结构的衍生物及其制备方法和有机电致发光器件
CN111499607B (zh) * 2019-01-30 2022-04-19 哈尔滨工业大学(深圳) 一种六元芳基内酯或六元芳基内酰胺化合物的制备方法
EP4263807A2 (de) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Verarbeitung von tumorinfiltrierenden lymphozyten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635941A (en) * 1969-04-01 1972-01-18 Eastman Kodak Co Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
GB1379387A (en) * 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3907507A (en) * 1971-04-26 1975-09-23 Heliodoro Monroy Rivera Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
DE69132006T2 (de) * 1990-11-30 2000-08-03 Otsuka Pharma Co Ltd Thiazolederivate als inhibitoren von aktivem sauerstoff
JPH04316557A (ja) * 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd 6−アリール環状アントラニル酸誘導体

Also Published As

Publication number Publication date
CN1626534A (zh) 2005-06-15
EP1382597A2 (de) 2004-01-21
EP1041071A1 (de) 2000-10-04
NO20003550L (no) 1997-08-14
NO20003534L (no) 1997-08-14
ATE269336T1 (de) 2004-07-15
JPH10510840A (ja) 1998-10-20
RU2191774C2 (ru) 2002-10-27
NO20003550D0 (no) 2000-07-10
PT800519E (pt) 2004-03-31
DK0800519T3 (da) 2004-03-01
ATE252560T1 (de) 2003-11-15
NO20003551L (no) 1997-08-14
CN1175247A (zh) 1998-03-04
NZ300739A (en) 2000-05-26
DE69533180T2 (de) 2005-07-14
CN1172917C (zh) 2004-10-27
CZ176197A3 (cs) 1998-09-16
NO20003552L (no) 1997-08-14
BR9510486A (pt) 1998-06-02
NO972591L (no) 1997-08-14
AU717251B2 (en) 2000-03-23
DE69531998T2 (de) 2004-07-22
NO20003551D0 (no) 2000-07-10
NO20003534D0 (no) 2000-07-07
NO312162B1 (no) 2002-04-02
NO20003552D0 (no) 2000-07-10
AU4597796A (en) 1996-07-10
JP2007217418A (ja) 2007-08-30
WO1996019458A2 (en) 1996-06-27
DE69533180D1 (de) 2004-07-22
EP1041066A1 (de) 2000-10-04
EP0800519B1 (de) 2003-10-22
EP1043315A1 (de) 2000-10-11
DE69531998D1 (de) 2003-11-27
HUT78117A (hu) 1999-11-29
WO1996019458A3 (en) 1996-12-12
EP0800519A1 (de) 1997-10-15
CA2208347A1 (en) 1996-06-27
EP1382597A3 (de) 2004-04-07
EP1043325B1 (de) 2004-06-16
NO312098B1 (no) 2002-03-18
NO972591D0 (no) 1997-06-06
ES2208699T3 (es) 2004-06-16
EP1043326A1 (de) 2000-10-11
NO313049B1 (no) 2002-08-05
EP1043325A1 (de) 2000-10-11

Similar Documents

Publication Publication Date Title
NO310617B1 (no) Steroidreseptormodulatorforbindelser, farmasöytiske sammensetninger inneholdende disse, samt anvendelse avforbindelsene eller sammensetningene for fremstilling avmedikamenter
US6121450A (en) Intermediates for preparation of steroid receptor modulator compounds
US6696459B1 (en) Steroid receptor modulator compounds and methods
US6017924A (en) Androgen receptor modulator compounds and methods
EP0918774B9 (de) Androgen rezeptor modulator verbindungen und verfahren
WO2001016133A2 (en) 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
AU762398B2 (en) Steroid receptor modulator compounds and methods
HUT78121A (hu) Androgén receptor modulátor kondenzált kinolin- és indolszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
MXPA98010831A (en) Compounds and modulators of androge receiver
AU2003248406A1 (en) Steroid receptor modulator compounds and methods